Ramelteon

Synonyms: TAK-375

Ramelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.

Ramelteon Chemical Structure

Ramelteon Chemical Structure

CAS No. 196597-26-9

Purity & Quality Control

Ramelteon Related Products

Biological Activity

Description Ramelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.
Features A tricyclic synthetic analog of melatonin.
Targets
MT1 receptor [1]
(Cell-free assay)
MT receptor (chicken) [1]
(Cell-free assay)
MT2 receptor [1]
(Cell-free assay)
14 pM(Ki) 23.1 pM(Ki) 112 pM(Ki)
In vitro
In vitro Ramelteon inhibits forskolin-stimulated cAMP production with IC50 of 21.2 pM in CHO cells. [1] Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively. Ramelteon inhibits Xenopus laevis melanophore pigment granule aggregation with pEC50 of 11.48. [2] Ramelteon (1 nM) increases ERK1/2 phosphorylation not only in MT1/MT2 cerebellar granule cells but also in cerebellar granule cells expressing only one of the two melatonin receptors. 4P-PDOT blocks the stimulatory action of Ramelteon (1 nM) in MT1 KO cerebellar granule cells, while luzindole attenuates the action of Ramelteon (1 nM) in MT2 KO cerebellar granule cells. Ramelteon (100 μM) induces any pigment dispersion while melatonin completely disperses aggregated melanophores at 10 μM. [3]
In Vivo
In vivo Ramelteon (10 mg/kg, i/p) significantly reduces NREM sleep latency in rat and also produces a short-lasting increase in nonrapid eye movement (NREM) sleep duration, but the NREM power spectrum is unaltered. [2] Ramelteon (0.1 mg/kg and 1 mg/kg, p.o.) accelerates reentrainment of running wheel activity rhythm to the new lightdark cycle in rats without affecting learning or memory. [4] Ramelteon (0.03 mg/kg and 0.3 mg/kg, p.o.) significantly shortens latency to sleep onset and significantly increases total duration of sleep in freely moving monkeys without affecting the general behavior of the monkeys. [5]
Animal Research Animal Models estrogen-deficient ovariectomized (OVX) rats
Dosages 1 mg/kg
Administration Orally
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03931070 Completed
Delirium
Rhode Island Hospital
May 9 2019 Phase 4
NCT02560324 Completed
Tobacco Use Disorder
University of Pennsylvania|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH)
September 2015 Phase 2
NCT02969343 Completed
Central Line-Associated Bloodstream Infection (CLABSI)|Venous Thromboembolism|Patient Fall|Catheter-Associated Infection|Severe Hypoglycemia|Opioid-Related Severe Adverse Drug Event|Hospital Acquired Pressure Ulcer|Adverse Drug Event|Severe Hospital Acquired Delerium|Rapid Response Related to Arrhythmia
Brigham and Women''s Hospital|Northeastern University
April 2015 Not Applicable
NCT00568789 Completed
Insomnia
Takeda
June 2006 Phase 4

Chemical Information & Solubility

Molecular Weight 259.34 Formula

C16H21NO2

CAS No. 196597-26-9 SDF Download Ramelteon SDF
Smiles CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 51 mg/mL ( (196.65 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ramelteon | Ramelteon ic50 | Ramelteon price | Ramelteon cost | Ramelteon solubility dmso | Ramelteon purchase | Ramelteon manufacturer | Ramelteon research buy | Ramelteon order | Ramelteon mouse | Ramelteon chemical structure | Ramelteon mw | Ramelteon molecular weight | Ramelteon datasheet | Ramelteon supplier | Ramelteon in vitro | Ramelteon cell line | Ramelteon concentration | Ramelteon nmr